NF-κB Suppresses the Expression of ATP-binding Cassette Transporter A1/G1 by Regulating SREBP-2 and Mir-33A in Mice
Guo-Jun Zhao,Shi-Lin Tang,Yun-Cheng Lv,Xin-Ping Ouyang,Ping-Ping He,Feng Yao,Yan-Yan Tang,Min Zhang,Ya-Ling Tang,Deng-Pei Tang,Francisco S. Cayabyab,Guo-Ping Tian,Chao-Ke Tang
DOI: https://doi.org/10.1016/j.ijcard.2013.11.093
IF: 4.039
2014-01-01
International Journal of Cardiology
Abstract:Efflux of cholesterol from peripheral tissues followed by its subsequent transport to the liver is proposed as an antiatherogenic mechanism [[1]Zanotti I. Favari E. Bernini F. Cellular cholesterol efflux pathways: impact on intracellular lipid trafficking and methodological considerations.Curr Pharm Biotechnol. 2012; 13: 292-302Crossref PubMed Scopus (42) Google Scholar]. The principal molecules involved in the efflux of cholesterol from macrophage foam cells are ATP-binding cassette transporters, ABCA1 and ABCG1, which promote cholesterol efflux to apoA-I and HDL, respectively [[2]Ye D. Lammers B. Zhao Y. et al.ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis.Curr Drug Targets. 2011; 12: 647-660Crossref PubMed Scopus (102) Google Scholar]. Recently, several prediction algorithms have predicted the presence of the microRNA-33a (miR-33a) binding sites in the 3′UTRs of genes involved in cholesterol transport, including ABCA1 and ABCG1 [3Najafi-Shoushtari S.H. Kristo F. Li Y. et al.MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis.Science. 2010; 328: 1566-1569Crossref PubMed Scopus (807) Google Scholar, 4Rayner K.J. Suarez Y. Davalos A. et al.MiR-33 contributes to the regulation of cholesterol homeostasis.Science. 2010; 328: 1570-1573Crossref PubMed Scopus (1034) Google Scholar, 5Horie T. Ono K. Horiguchi M. et al.MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo.Proc Natl Acad Sci U S A. 2010; 107: 17321-17326Crossref PubMed Scopus (332) Google Scholar]. The mature forms of miR-33a are coexpressed with the transcription factor host gene SREBP-2 (sterol-regulatory-element-binding protein-2), which acts primarily on the cholesterol biosynthetic genes and LDL receptor (LDLr) gene [[6]Wijesekara N. Zhang L.H. Kang M.H. et al.miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets.Diabetes. 2012; 61: 653-658Crossref PubMed Scopus (117) Google Scholar]. Major studies focus on how miR-33a regulates the expression of predicted target genes, but studies on the regulation of miR-33a in cells are few. Therefore, identifying potential regulators of miR-33a production should ultimately provide novel information about cholesterol efflux mechanisms that can be harnessed for anti-atherogenic therapy. Here, we describe the effects of nuclear factor-kappa B (NF-κB), which is frequently activated as a key transcription activator for the downstream response genes, on the expression of miR-33a in vitro and in vivo. ABCA1, ABCG1 and SREBP-2 detection was performed using quantitative real-time PCR (qRT-PCR) as previously reported [[7]Tian G.P. Chen W.J. He P.P. et al.MicroRNA-467b targets LPL gene in RAW 264.7 macrophages and attenuates lipid accumulation and proinflammatory cytokine secretion.Biochimie. 2012; 94: 2749-2755Crossref PubMed Scopus (48) Google Scholar]. For miR-33a assays, total RNA was extracted from cells using miRVana miRNA isolation kit and quantified using the TaqMan microRNA assay kit for mmu-miR-33a, with U6 RNA used as an internal control. Cells or murine tissues were harvested and protein levels (for ABCA1, ABCG1, SREBP-2, NF-κB p65 or β-actin) were analyzed using Western blots. The activity of SREBP-2 promoter was measured using a Perkin-Elmer 1420 multilabel counter according to the instructions of the Dual-luciferase reporter assay system (Promega), and values were normalized to Renilla luciferase activity. Six-week old male apoE−/− mice were randomly divided into several groups (n = 15 per group). To activate NF-κB, the lipopolysaccharide (LPS) group was challenged intraperitoneally (i.p.) with LPS (2.5 mg/kg body wt) in 200 μl of PBS once every week. To selectively inhibit NF-κB, mice in the pyrrolidine dithiocarbamate (PDTC) group were injected i.p. with PDTC (50 mg/kg body wt) 1 h before LPS challenge. At week 16, the mice were sacrificed and 8 μm thick sections were cut through the aortic sinus. Twenty sections per animal were stained for lipids with Oil-red O and counter-stained with Gill III hematoxylin. Lesion areas were quantified with ImagePro Plus. NF-κB activation induced by LPS decreased the levels of ABCA1/G1, and application of the NF-κB specific inhibitor PDTC significantly prevented the NF-κB-induced suppression of ABCA1 and ABCG1 expression (Fig. 1A and B ). Recent studies have shown that miR-33a produced from an intron of SREBP-2 inhibits cholesterol efflux by down-regulating ABCA1 and ABCG1 expression at the post-transcriptional level. To investigate how NF-κB suppresses ABCA1 and ABCG1, we examined the levels of miR-33a and its host gene SREBP-2. As shown in Fig. 1C, NF-κB activation by LPS increased the mRNA level of SREBP-2 and miR-33a. Since the SREBP-2 promoter region contains a putative NF-κB response element (κBRE), we hypothesized that SREBP-2 might be NF-κB target gene. We fused the mouse SREBP-2 promoter region to a luciferase reporter and evaluated its activity in transiently transfected RAW264.7 macrophages. LPS-induced activation of NF-κB significantly increased the luciferase activity of SREBP-2 promoter containing the putative κBRE, while mutation or deletion of the putative κBRE essentially abolished the inductive effect of NF-κB on SREBP-2 promoter activity (Fig. 1D and E). Next, we used siRNA transfections to determine whether SREBP-2 and miR-33a were involved in the inhibitory effect of NF-κB on ABCA1/G1 expression. The ability of NF-κB to suppress ABCA1/G1 in LPS-stimulated macrophages was significantly impaired by the application of SREBP-2 siRNA (Fig. 1F–H), suggesting that NF-κB-induced ABCA1/G1 suppression is mediated by SREBP-2. We next determined whether our in vitro findings reflected in vivo circumstances. Eight-week-old male apoE−/− mice were challenged intraperitoneally with LPS in the absence or presence of PDTC for 8 weeks. Peritoneal macrophages were isolated. Protein levels of various proteins were determined from immunoblots. As shown in Fig. 2A and B , LPS treatment dramatically increased the protein levels of NF-κB and SREBP-2 as well as miR-33a expression, but reduced the protein levels of ABCA1 and ABCG1. The NF-κB inhibition by PDTC partially but significantly prevented the LPS-induced NF-κB activation and subsequent changes in the expressions of SREBP-2, miR-33a, ABCA1 and ABCG1. That is, PDTC reduced the levels of SREBP-2 and miR-33a, but increased the levels of ABCA1 and ABCG1. We also observed that apoE−/− mice injected with LPS with or without PDTC showed a significant reduction in atherosclerotic lesion sizes with NF-κB inhibition (Fig. 2C). These findings indicate that NF-κB regulates SREBP-2 and miR-33a in vivo in apoE−/− mice. Immune and inflammatory response processes play important roles in the induction of atherosclerotic lesions [[8]Zernecke A. Weber C. Improving the treatment of atherosclerosis by linking anti-inflammatory and lipid modulating strategies.Heart. 2012; 98: 1600-1606Crossref PubMed Scopus (10) Google Scholar]. The mechanisms and the potential therapeutic implications linking inflammation to atherosclerosis warrant investigation. In the present study, we firstly explored the potential link between NF-κB activation by LPS and mechanisms that control cholesterol accumulation in RAW264.7 macrophages. We showed for the first time that NF-κB activation leads to increased expression of SREBP-2 and its intronic miR-33a. We also demonstrated that NF-κB directly bound to the κBRE of the SREBP-2 promoter. Furthermore, inhibition of SREBP-2 by siRNA significantly prevented the LPS-induced downregulation of ABCA1/G1 expression. These results suggest that NF-κB could attenuate ABCA1/G1 ex\NF-κB-mediated activation of the expression of SREBP-2 and miR-33a. Although the exact cross-talk between chronic inflammation and NF-κB-mediated changes in SREBP-2, miR-33a, and ABCA1/G1 remains to be clarified, our studies performed in mice indicate that selective NF-κB inhibition during inflammatory processes should promote normal cholesterol efflux from macrophage foam cells. Whether this potential anti-atherosclerotic therapy is applicable to humans remains to be determined. This work was supported by the financial support from the National Natural Sciences Foundation of China (81200218, 81070220, 81370377 and 81170278), Aid Program for Science and Technology Innovative Research Team in Higher Educational Institutions (2008-244) of Hunan Province, and the construct program of the key discipline in Hunan Province, China. The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology. Corrigendum to "NF-κB suppresses the expression of ATP-binding cassette transporter A1/G1 by regulating SREBP-2 and miR-33a in mice" [Int J Cardiol 171 (2014) e93–e95]International Journal of CardiologyVol. 176Issue 2PreviewDetails of both corresponding authors should be corrected as follows: Full-Text PDF